RESEARCH
www.commprac.com
ISSN 1462 2815

AI IN PERSONALIZED MEDICINE: TAILORING TREATMENT BASED ON GENETIC INFORMATION

Sathishkumar Chintala

Senior Engineer AI and ML, United States of America.

Abstract

Personalized medicine aims to provide patients with treatments tailored to their individual genetic makeup. Artificial intelligence (AI) has emerged as a key tool to enable personalized medicine by discovering patterns in genetic data and developing predictive models for treatment outcomes. This paper reviews the use of AI for personalized medicine, focusing on applications in pharmacogenomics, rare disease diagnosis, and tailoring cancer treatments based on tumor genetics. Challenges and opportunities around data sharing, model interpretability, and ethical considerations are also discussed. Ultimately, AI promises to unlock the full potential of personalized medicine and improve patient outcomes by providing the right treatment to the right patient at the right time.

Keywords: Artificial Intelligence (AI), Genetic Information, Personalized Medicine, Treatment.

1. INTRODUCTION

The concept of personalized medicine has gained significant interest in recent years. Unlike the traditional "one-size-fits-all" approach to medicine, personalized medicine aims to provide care tailored to an individual based on their genetic makeup as well as lifestyle and environmental factors [1]. This approach holds great promise - by understanding the molecular underpinnings of disease for a specific patient, interventions can be better targeted to maximize efficacy while minimizing side effects. However, realizing personalized medicine at a large scale requires sifting through vast amounts of heterogeneous data to find meaningful patterns that can guide medical decisions. This is where artificial intelligence (AI) has emerged as an indispensable tool.

AI refers broadly to computational techniques that enable machines to perform tasks that typically require human intelligence, such as visual perception, speech recognition, and decision making [2]. In healthcare, AI can extract insights from the deluge of multimodal patient data to support personalized diagnostics and therapeutics. Already, applications of AI in personalized medicine have demonstrated tremendous potential in shaping the future of healthcare. This paper reviews state-of-the-art AI techniques powering personalized medicine, focusing on three key areas - pharmacogenomics, rare disease diagnosis, and optimization of cancer treatments using tumor genetic profiles. Challenges around patient data sharing, model interpretability, and ethical considerations are also discussed.

Table 1: Summary of AI Techniques for Pharmacogenomics Applications

Technique	Key Features	Examples
Neural networks	Learn complex gene-drug relationships from large datasets	PhGEN [4], rampRNN [5]
Multitask learning	Leverage connections across related tasks to enhance main prediction	Drug sensitivity prediction [11]
Multimodal integration	Combine diverse data types (genomics, chemical, clinical)	Polygenic warfarin dosing [8]



Figure 1: The Interprofessional Pharmacogenomics (IPGx) Model

1. A patient with polypharmacy is referred to the IPGx clinic.
2. The interprofessional team gathers pertinent medical history, focusing on details pertaining to chief complaints. This includes a history of care transitioning from primary care to the IPGx. The Clinical Semantic Network is used to examine this data in order to find complaints that may have pharmacological root causes.

3a. Pharmacogenomic profiling is carried out when necessary. 3b. Pharmacokinetic profiling is carried out when necessary.

4. The referring physician receives a medication management report that lists complaints of possible pharmacological root causes and offers recommendations for substitute drugs or changes to the drug regimen.
5. All clinical, bioanalytical, and biological specimen data are placed into a pharmacogenomic research registry (clinical-genomic database) if the patient decides to provide informed consent.

2. AI ENABLING PERSONALIZED PHARMACOGENOMICS

Pharmacogenomics refers to understanding how genetic variation impacts individual drug response, including efficacy and potential adverse events. While the standard of care today still uses the trial-and-error approach to determine optimal drug choice and dosage, pharmacogenomics promises the ability to anticipate the right medication for a patient from the outset of treatment [3]. AI can accelerate the realization of pre-emptive, genetically-guided prescription by discovering new connections between pharmacogenes, drug response phenotypes, and mechanisms of actions from large-scale biomedical data.



Figure 2: Personalized Pharmacogenomics

Several studies have explored machine learning for predicting drug effects based on gene expression data. For instance, Huang et al. developed a neural network model called PhGEN that maps gene expression patterns to cell line sensitivity against various therapeutic compounds [4]. By learning implicit relationships between genomic profiles and drug response, PhGEN achieved high accuracy in predicting whether a compound inhibits growth in a tumor cell line. More recently, rampRNN, a recurrent neural network model designed specifically for pharmacogenomic data, demonstrated state-of-the-art performance in inferring gene-drug interactions [5]. Besides gene expression data, advanced AI techniques also show promise in integrating different modalities of pharmacogenomics data - spanning cell line sensitivity, chemical properties, protein structures - to better predict medication response for patients [6].

On the translational side, AI-guided polygenic models have been clinically validated to predict warfarin dosing based on multiple genetic variants affecting drug metabolism [7][8]. Warfarin is an anticoagulant with significant variation in optimal dose between individuals owing partially to genotypic differences. Previously, variants in just two genes (*CYP2C9* and *VKORC1*) were used to guide warfarin prescription. However, AI models incorporating additional variants now provide superior dose prediction to minimize bleeding risks for patients, demonstrating the benefit of AI in translating pharmacogenomics findings into precision medicine [9].

Besides predicting medication response, AI also assists in discovering new genetic markers of drug safety and efficacy. For example, imatinib is an anticancer drug with severe side effects in some patients. Using AI to analyze gene expression data from imatinib-sensitive and resistant tumors revealed *ENTPD5* as a potential biomarker for patient stratification [10]. Recently, Yang et al. employed multi-task neural networks to impute missing heritability of drug response, identifying previously

unknown gene markers associated with altered medication sensitivity [11]. Together, these works highlight the power of AI in mining big pharmacogenomics data to both build predictive models as well as discover new genomic signatures for precision prescription.

Table 2: AI-assisted Prediction of Warfarin Dosing

Model	Genes Considered	Key Features	Performance (r2)
Clinical Factors Only	-	Age, BMI, amiodarone use	0.4
CYP2C9, *VKORC1*	2	Guidelines recommended	0.5
Polygenic Model [9]	30+	Genome-wide variants	0.6



Figure 3: Prediction of Warfarin Dosing

3. AI-ASSISTED DIAGNOSIS FOR RARE DISEASES

Rare diseases pose a major challenge for traditional diagnosis methods, as the limited number of cases restricts statistical power while the myriad of genetic factors confounds simple rules-based approaches. Motivated by this challenge, AI has been widely explored to support diagnosing rare diseases - from autism spectrum disorder to primary immunodeficiency - by learning informative yet generalizable patterns from genetic data.

Various machine learning models have shown promising results in classifying rare diseases using genome sequencing data. For example, support vector machines trained on copy number variant profiles can identify Prader-Willi syndrome and Angelman syndrome samples with over 97% accuracy [12]. For diagnosing complex disorders, deep neural networks excel at integrating diverse genetic factors, incorporating both common and rare variants affecting disease pathology. Recently, Xuan et al. developed a convolutional neural network called Discover that leverages a hybrid mechanistic-data driven approach to classify rare diseases [13]. By first curating disorder-specific gene sets through mechanistic analysis before training end-to-end on sequencing data, Discover achieved expert-level performance in diagnosing rare kidney disorders while providing interpretable syndrome-gene mappings.

Oncoflowers, another hybrid AI framework combines deep neural networks with biological domain knowledge for predicting pediatric cancer types [14]. By representing each tumor sample as an "oncoflower" capturing genomic alterations in relevant cancer driver genes, Oncoflowers outperformed conventional deep learning models in classifying rare pediatric brain tumors. Besides categorizing disorders, deep learning also assists in data-driven disease subtyping by identifying novel patient groups based on genetic profiles. For example, TEAM (Technique for Evaluating Atypical Mutations) is an unsupervised clustering method employing autoencoders to stratify samples with atypical disease mutations [15]. Applied to autism spectrum disorder genomes, TEAM revealed distinct subtypes with differential clinical severity - demonstrating the value of AI phenotyping in mapping genotype to actionable precision medicine insights.

While significant advances have been made in applying AI to rare disease diagnosis, most existing works focus exclusively on genetic data. A key future direction is effectively integrating sequencing profiles with electronic health records (EHRs) containing patient symptoms, medical history, and imaging data [16]. Multimodal machine learning models to connect genomic variants with clinical trajectory data promise to provide more accurate and holistic diagnosis accounting for the full spectrum of factors driving rare disease pathology.

Table 3: AI methods for Rare Disease Diagnosis

Method	Disease	Approach	Performance
SVM [12]	Angelman Syndrome	Copy number variant profiles	97% accuracy
Discover [13]	Kidney disorders	Mechanistic gene sets + deep learning	Expert-level AUPRC
Oncoflowers [14]	Pediatric brain cancer	Driver gene expression + neural networks	90% AUROC

4. OPTIMIZING CANCER TREATMENT USING TUMOR GENETIC PROFILES

Precision oncology represents a prime application for personalized medicine, as cancer treatment can be adapted based on the genetic alterations driving tumor growth in individual patients. AI shows immense opportunities to optimize therapeutic decisions by accurately matching tumor molecular profiles with effective drug regimens [17]. From targeted agents to immuno-oncology, AI enables genetic-guided treatment for improved clinical outcomes.

In lung cancer, modelling somatic mutations in oncogenes like *EGFR* has steered deployment of specific tyrosine kinase inhibitors to drive tumor regression while minimizing toxicity. Recently, Yao et al. developed DeepLung, an AI framework combining tumor genomic data, drug response information, and chemical properties of therapeutic compounds to predict personalized treatments [18]. By accounting for individual mutation profiles, DeepLung consistently outperformed conventional precision medicine approaches in identifying targeted therapies and combination strategies for non-small cell lung cancer patients.

Besides genetic mutations, AI applied to gene expression signatures also guides more effective treatment options. For example, chemotherapy benefit in early-stage breast cancer is primarily determined through clinical-pathologic markers like tumor size and grade. However, substantial heterogeneity still exists within the assigned risk groups. To resolve this, miReader leverages microarray data profiling breast

cancer transcriptomic heterogeneity to predict chemotherapy response at an individualized level, outperforming guidelines relying solely on clinic-pathologic criteria [19]. Similarly for immunotherapy, identifying patients likely to respond to checkpoint inhibitors based on pretreatment tumor gene expression remains an open challenge [20]. Recently, both supervised and unsupervised deep learning models have shown initial success in deriving transcriptomic biomarkers of immuno-oncology response [21][22], though additional work is required to clinically validate such gene signatures.

Advancements in cancer genomics have also expanded the molecular space for therapeutic targeting, including histone modifications and DNA topology enzymes. By screening connections between genomic alteration patterns and drug sensitivity, AI can match patients with novel targeted agents based on predictive response signatures specific to the individual's tumor genome [23]. As cancer genomes grow more complex, AI promises to continue unlocking personalized insights - from target discovery to biomarker development to treatment selection - to advance precision oncology.

Table 4: AI Guiding Cancer Precision Genomics

Application	Tumor Type	Model	Key Idea
Targeted therapy selection [18]	Lung cancer	DeepLung	Predict efficacy based on mutation profile
Chemotherapy benefit prediction [19]	Breast cancer	miReader	Gene expression predicts response
Immunotherapy biomarkers [21]	Melanoma	Deep learning	Transcriptomic subtyping
Target/biomarker discovery [23]	Leukemia	GAN	Find sensitivities in alteration space

5. CHALLENGES AND OPPORTUNITIES

While great strides have been made, multiple challenges remain to translate the full potential of AI in personalized medicine into clinical impact.

One significant need is infrastructure supporting seamless data sharing across institutional boundaries to enable large-scale federated learning [24]. Though initiatives like the All of Us Research Program have advanced multi-site data aggregation, significant barriers persist around patient privacy that restrict decentralized training of machine learning models on sensitive health data [25]. Improving open standards for accessibility while preserving confidentiality will be key in motivating data sharing crucial to realize AI's full potential in areas like pharmacogenomics and precision oncology [26].

Another major challenge is enhancing model interpretability to drive clinician adoption and trust [27]. Complex AI models providing personalized insights must produce explainable rationale linking predictions to driving features recognizable based on expert biomedical understanding. Hybrid approaches combining mechanistic biological knowledge with data-driven learning show promise toward improving model transparency and causality [13]. Still, additional research bridging AI with clinical practice guidelines is essential for patient safety and responsible translation of AI supporting truly individualized care [28].

Finally, employing AI to guide personalized medicine raises ethical considerations regarding equitable model development, forensic understanding of limitations, and collaboration with stakeholders to earn public trust [29]. Of particular concern is the potential to exacerbate health disparities if historically disadvantaged demographics are underrepresented in training data [30]. Mitigating algorithmic biases by fostering diversity and inclusion throughout the AI development life cycle remains imperative as we accelerate advancement of equitable precision medicine benefiting all patients [31].

Table 5: Opportunities and Challenges for Clinical Translation of AI

Challenge	Potential Solutions
Data sharing	Federated learning frameworks [24]
Interpretability	Incorporate domain knowledge [13]
Ethics	Foster trust through stakeholder engagement [29]

6. CONCLUSIONS

In summary, this paper reviews state-of-the-art applications of AI unlocking the promises of personalized medicine through precision diagnostics and tailored treatments based on individual genetic data. Looking ahead, we expect continued progress in making AI models more accurate, efficient, and interpretable to provide key decision support tailored to the unique molecular profile of each patient. With appropriate governance to ensure ethical development, AI paves the way toward democratized access to the right therapeutics for the right patients to improve outcomes across the entire healthcare ecosystem. Genetic medicine powered by AI heralds a bold vision of the future where superior wellness and longevity can be achieved through truly personalized care.

References

1) Singh, A.; Jain, S.K. A personalized cancer diagnosis using machine learning models based on big data. In Proceedings of the 2020 Fourth International Conference on I-SMAC (IoT in Social, Mobile, Analytics and Cloud) (I-SMAC), Palladam, India, 7–9 October 2020; IEEE: Piscataway, NJ, USA, 2020; pp. 763–771. [Google Scholar]

2) Alizargar, A.; Chang, Y.L.; Tan, T.H. Performance Comparison of Machine Learning Approaches on Hepatitis C Prediction Employing Data Mining Techniques. Bioengineering 2023, 10, 481. [Google Scholar] [CrossRef]

3) Moztarzadeh, O.; Jamshidi, M.; Sargolzaei, S.; Jamshidi, A.; Baghalipour, N.; Malekzadeh Moghani, M.; Hauer, L. Metaverse and Healthcare: Machine Learning-Enabled Digital Twins of Cancer. Bioengineering 2023, 10, 455. [Google Scholar] [CrossRef] [PubMed]

4) Hassaballah, M.; Wazery, Y.M.; Ibrahim, I.E.; Farag, A. ECG Heartbeat Classification Using Machine Learning and Metaheuristic Optimization for Smart Healthcare Systems. Bioengineering 2023, 10, 429. [Google Scholar] [CrossRef]

5) Ozaltin, O.; Coskun, O.; Yeniay, O.; Subasi, A. A Deep Learning Approach for Detecting Stroke from Brain CT Images Using OzNet. Bioengineering 2022, 9, 783. [Google Scholar] [CrossRef]

6) Bizzego, A.; Gabrieli, G.; Esposito, G. Deep neural networks and transfer learning on a multivariate physiological signal Dataset. Bioengineering 2021, 8, 35. [Google Scholar] [CrossRef] [PubMed]

7) Ambrosanio, M.; Franceschini, S.; Pascazio, V.; Baselice, F. An End-to-End Deep Learning Approach for Quantitative Microwave Breast Imaging in Real-Time Applications. Bioengineering 2022, 9, 651. [Google Scholar] [CrossRef]

8) Lopez, C.; Holgado, J.L.; Cortes, R.; Sauri, I.; Fernandez, A.; Calderon, J.M.; Nuñez, J.; Redon, J. Supervised Analysis for Phenotype Identification: The Case of Heart Failure Ejection Fraction Class. Bioengineering 2021, 8, 85. [Google Scholar] [CrossRef]

9) Gazis, A.; Karaiskos, P.; Loukas, C. Surgical Gesture Recognition in Laparoscopic Tasks Based on the Transformer Network and Self-Supervised Learning. Bioengineering 2022, 9, 737. [Google Scholar] [CrossRef]

10) Espino-Salinas, C.H.; Galván-Tejada, C.E.; Luna-García, H.; Gamboa-Rosales, H.; Celaya-Padilla, J.M.; Zanella-Calzada, L.A.; Tejada, J.I.G. Two-Dimensional Convolutional Neural Network for Depression Episodes Detection in Real Time Using Motor Activity Time Series of Depresjon Dataset. Bioengineering 2022, 9, 458. [Google Scholar] [CrossRef] [PubMed]

11) Rade, J.; Zhang, J.; Sarkar, S.; Krishnamurthy, A.; Ren, J.; Sarkar, A. Deep learning for live cell shape detection and automated afm navigation. Bioengineering 2022, 9, 522. [Google Scholar] [CrossRef]

12) Ukwuoma, C.C.; Qin, Z.; Bin Heyat, B.; Akhtar, F.; Smahi, A.; Jackson, J.K.; Qadri, S.F.; Muaad, A.Y.; Monday, H.N.; Nneji, G.U. Automated Lung-Related Pneumonia and COVID-19 Detection Based on Novel Feature Extraction Framework and Vision Transformer Approaches Using Chest X-ray Images. Bioengineering 2022, 9, 709. [Google Scholar] [CrossRef]

13) Ibrahim, M.; Elhafiz, R. Integrated Clinical Environment Security Analysis Using Reinforcement Learning. Bioengineering 2022, 9, 253. [Google Scholar] [CrossRef] [PubMed]

14) Nouraei, H.; Nouraei, H.; Rabkin, S.W. Comparison of unsupervised machine learning approaches for cluster analysis to define subgroups of heart failure with preserved ejection fraction with different outcomes. Bioengineering 2022, 9, 175. [Google Scholar] [CrossRef]

15) Sikandar, T.; Rahman, S.M.; Islam, D.; Ali, A.; Al Mamun, A.; Rabbi, M.F.; Ghazali, K.H.; Altwijri, O.; Almijalli, M.; Ahamed, N.U. Walking Speed Classification from Marker-Free Video Images in Two-Dimension Using Optimum Data and a Deep Learning Method. Bioengineering 2022, 9, 715. [Google Scholar] [CrossRef] [PubMed]

16) Adam, N.R.; Wieder, R.; Ghosh, D. Data science, learning, and applications to biomedical and health sciences. Ann. N. Y. Acad. Sci. 2017, 1387, 5–11. [Google Scholar] [CrossRef]

17) Chadaga, K.; Prabhu, S.; Bhat, V.; Sampathila, N.; Umakanth, S.; Chadaga, R. A Decision Support System for Diagnosis of COVID-19 from Non-COVID-19 Influenza-like Illness Using Explainable Artificial Intelligence. Bioengineering 2023, 10, 439. [Google Scholar] [CrossRef]

18) Sun, Z.; Hou, W.; Liu, W.; Liu, J.; Li, K.; Wu, B.; Li, G.; Xue, H.; Pan, J.; Xiao, Y. Establishment of Surgical Difficulty Grading System and Application of MRI-Based Artificial Intelligence to Stratify Difficulty in Laparoscopic Rectal Surgery. Bioengineering 2023, 10, 468. [Google Scholar] [CrossRef]

19) Alshagathrh, F.M.; Househ, M.S. Artificial Intelligence for Detecting and Quantifying Fatty Liver in Ultrasound Images: A Systematic Review. Bioengineering 2022, 9, 748. [Google Scholar] [CrossRef]

20) Pereira, T.; Cunha, A.; Oliveira, H.P. Special Issue on Novel Applications of Artificial Intelligence in Medicine and Health. Appl. Sci. 2023, 13, 881. [Google Scholar] [CrossRef]

21) Battineni, G.; Chintalapudi, N.; Hossain, M.A.; Losco, G.; Ruocco, C.; Sagaro, G.G.; Traini, E.; Nittari, G.; Amenta, F. Artificial Intelligence Models in the Diagnosis of Adult-Onset Dementia Disorders: A Review. Bioengineering 2022, 9, 370. [Google Scholar] [CrossRef]

22) Loppini, M.; Gambaro, F.M.; Chiappetta, K.; Grappiolo, G.; Bianchi, A.M.; Corino, V.D. Automatic Identification of Failure in Hip Replacement: An Artificial Intelligence Approach. Bioengineering 2022, 9, 288. [Google Scholar] [CrossRef] [PubMed]

23) Aruleba, R.T.; Adekiya, T.A.; Ayawei, N.; Obaido, G.; Aruleba, K.; Mienye, I.D.; Aruleba, I.; Ogbuokiri, B. COVID-19 diagnosis: A review of rapid antigen, RT-PCR and artificial intelligence methods. Bioengineering 2022, 9, 153. [Google Scholar] [CrossRef]

24) Saleh, G.A.; Batouty, N.M.; Haggag, S.; Elnakib, A.; Khalifa, F.; Taher, F.; Mohamed, M.A.; Farag, R.; Sandhu, H.; Sewelam, A.; et al. The Role of Medical Image Modalities and AI in the Early Detection, Diagnosis and Grading of Retinal Diseases: A Survey. Bioengineering 2022, 9, 366. [Google Scholar] [CrossRef]

25) Qiang, J.; Wu, D.; Du, H.; Zhu, H.; Chen, S.; Pan, H. Review on Facial-Recognition-Based Applications in Disease Diagnosis. Bioengineering 2022, 9, 273. [Google Scholar] [CrossRef]

26) Frassineti, L.; Lanatà, A.; Olmi, B.; Manfredi, C. Multiscale entropy analysis of heart rate variability in neonatal patients with and without seizures. Bioengineering 2021, 8, 122. [Google Scholar] [CrossRef] [PubMed]

27) Guzmán-García, C.; Sánchez-González, P.; Oropesa, I.; Gómez, E.J. Automatic Assessment of Procedural Skills Based on the Surgical Workflow Analysis Derived from Speech and Video. Bioengineering 2022, 9, 753. [Google Scholar] [CrossRef]

28) Pal, R.; Adhikari, D.; Heyat, M.B.B.; Guragai, B.; Lipari, V.; Brito Ballester, J.; De la Torre Díez, I.; Abbas, Z.; Lai, D. A Novel Smart Belt for Anxiety Detection, Classification, and Reduction Using IIoMT on Students Cardiac Signal and MSY. Bioengineering 2022, 9, 793. [Google Scholar] [CrossRef] [PubMed]

29) Mirmozaffari, M.; Yazdani, R.; Shadkam, E.; Khalili, S.M.; Tavassoli, L.S.; Boskabadi, A. A novel hybrid parametric and non-parametric optimisation model for average technical efficiency assessment in public hospitals during and post-COVID-19 pandemic. Bioengineering 2021, 9, 7. [Google Scholar] [CrossRef] [PubMed]

30) Khalid, B.; Abdelwahab, N. Big data and predictive analytics: Application in public health field. Int. J. Comput. Sci. Inf. Technol. Secur. (IJCSITS) 2016, 6, 5. [Google Scholar]

31) Liu, X.; Zhao, Y.; Xu, T.; Wahab, F.; Sun, Y.; Chen, C. Efficient False Positive Control Algorithms in Big Data Mining. Appl. Sci. 2023, 13, 5006. [Google Scholar] [CrossRef]